Background
==========

Only a small number of studies on collision tumors of lymphoma and colorectal adenocarcinoma exist \[[@B1]-[@B8]\]. In non-Hodgkin's lymphoma (NHL), the gastrointestinal tract is the most frequently involved extranodal site, with the stomach being the most common location (50% to 60%) followed by the small intestine (30%). Primary lymphoma of the colon is rare, comprising only 0.2% to 1.2% of all colonic malignancies \[[@B9]\]. Additionally, colon lymphomas represent 5.6% to 20% of all gastrointestinal lymphomas \[[@B10]\]. Furthermore, lymphoma synchronously accompanied by adenocarcinoma of the colon is extremely rare \[[@B6]\].

Case presentation
=================

An 81-year-old man presented to the Department of Chest Medicine as an outpatient with a chronic dry cough persisting for 1 month. There were no other systemic symptoms, excluding hypertension and benign prostate hyperplasia. Chest radiography revealed a 3.2-cm nodule in the right middle lung field. Bronchoscopic biopsy was performed, and the pathological examination revealed adenocarcinoma, which was considered to be colorectal in origin, as proved by a positive immunostaining reaction for cytokeratin 20 (Figure [1](#F1){ref-type="fig"}A) and caudal-related homeodomain transcription factor 2 (Figure [1](#F1){ref-type="fig"}B) as well as immunostaining reaction for cytokeratin 7 (Figure [1](#F1){ref-type="fig"}C) and thyroid transcription factor-1 (Figure [1](#F1){ref-type="fig"}D). The patient was then referred to the outpatient Department of Colorectal Surgery. After admission, a series of analyses were performed. The general examination was unremarkable, with no lymphadenopathy, and laboratory studies revealed a hemoglobin concentration of 11.9 g/dL, a white blood cell count of 5,800 cells/μL, and a platelet count of 154,000 cells/μL. Renal and liver function tests were normal, and hepatitis markers were negative. Serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels were 214 ng/mL and 1.21 U/mL, respectively. A complete colonoscopy revealed an annular ulcerative lesion in the sigmoid colon (25 cm above the anal verge). Biopsy of the tumor was performed, which revealed a moderately differentiated colon adenocarcinoma. Computed tomography of the abdomen and pelvis revealed mesenteric lymphadenopathies associated with a mass in the sigmoid colon (Figure [2](#F2){ref-type="fig"}A, arrow). There was no liver metastasis. Computed tomography of the thorax revealed a 3.2-cm nodule in the right middle lung field that was consistent with lung metastasis (Figure [2](#F2){ref-type="fig"}B, arrow). The patient underwent anterior resection associated with regional lymphadenectomy, with the pathological assessment of the resected specimen revealing a collision tumor consisting of a moderately differentiated adenocarcinoma extending through the muscularis propria and low-grade B-cell lymphoma. Extramural vascular invasion of the adenocarcinoma cells was present. Interestingly, there were several granulomatous lesions on the resected sigmoid colon. Acid-fast staining and polymerase chain reaction analysis of mycobacterial DNA revealed positive findings. Microscopic evaluation of the 19 regional lymph nodes in the mesentery of the resected colon showed diffuse infiltration of low-grade B-cell lymphoma in the lymph node architecture. In one lymph node, metastasis of adenocarcinoma was also present. According to immunohistochemistry, the cells were positive for cluster of differentiation (CD) 20, B-cell lymphoma (Bcl)-2, and CD10 (weak), and negative for CD3, CD5, CD23, Bcl-6, terminal deoxynucleotidyl transferase, and cyclin D1. The proliferation fraction (MIB-1 immunostaining) was approximately 15%. The morphological and immunohistochemical findings were used to confirm the diagnosis of synchronous presentation of low-grade B-cell lymphoma and colon adenocarcinoma within the sigmoid colon tumor and mesenteric lymph nodes. Furthermore, microscopic examination of the spleen revealed infiltration of the specimen by low-grade B-cell lymphoma with proliferation of small to medium-sized cells (Figure [3](#F3){ref-type="fig"}). *K-RAS* and *B-RAF* genetic mutations were evaluated in the primary tumor DNA after microdissection, and both genes were determined to be the wild type. Three weeks after surgery, the patient was scheduled to undergo a bone marrow biopsy for lymphoma staging, but he declined because of his advanced age and general poor condition.

![**Histological appearance of the lung biopsy specimen.** Malignant tumor cells were arranged in clusters and an acinar pattern, suggestive of adenocarcinoma. **(A)** Positive immunohistochemical staining for cytokeratin 20. **(B)** Positive immunohistochemical staining for caudal-related homeodomain transcription factor 2. **(C)** Negative immunohistochemical staining for cytokeratin 7. **(D)** Negative immunohistochemical staining for thyroid transcription factor-1.](1477-7819-12-147-1){#F1}

![**Computed tomography (CT) of the abdomen and chest. (A)** Abdominal CT revealed wall thickening of the sigmoid colon, which is compatible with colon cancer (arrow). **(B)** Chest CT revealed a 3.2-cm nodule in the right middle lung field (arrow).](1477-7819-12-147-2){#F2}

![**The spleen was infiltrated by low-grade B-cell lymphoma with the proliferation of small-to-medium-sized cells.** Hematoxylin and eosin, original magnification, ×100.](1477-7819-12-147-3){#F3}

After discussion of this case in a multidisciplinary team treatment conference for colorectal cancer, the patient underwent palliative chemotherapy with modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) for six cycles. However, he presented with grade III peripheral neuropathy in both hands and feet. On the basis of the late stage of the bowel malignancy, advanced age, and complexity of comorbidities of the patient, we proposed a palliative treatment with capecitabine, which is ongoing. He also received tuberculosis (TB) treatment, which included ethambutol, rifampicin, isoniazid, and pyrazinamide for the first 2 months, and then ethambutol, rifampicin, and isoniazid for the next 6 months, after extra-pulmonary TB was detected. He was regularly followed-up as an outpatient. The patient has remained in a stable condition for 24 months after surgical resection of the colon.

Discussion
==========

To our knowledge, this report is the first case of a collision tumor of low-grade B-cell lymphoma and adenocarcinoma in the same colonic segment, and retrieved lymph nodes coexisting with a TB infection.

The coexistence of TB and carcinoma is well documented in the lungs, skin, and larynx. However, the simultaneous occurrence of these two diseases is rarely observed in the colon. Chronic diseases, such as ulcerative colitis and Crohn's disease, are known to increase the risk of malignancy, but the causal relationship between carcinoma and TB in the colon is still unclear \[[@B11]\]. The etiological relationship between the two diseases is a matter of debate. The coexistence of TB and adenocarcinoma in the colon may be coincidental, or one disease process might have initiated the other \[[@B12]-[@B14]\]. Falagas et al. \[[@B15]\] reported that clinicians need to be aware of the protean manifestations of TB and cancer, and they should maintain a high index of suspicion for simultaneous and/or misleading presentations. TB and various types of malignancies can mimic each other and have atypical clinical and radiological expressions. Further research is required to determine whether TB infection, being similar to other chronic infections and inflammatory conditions, may facilitate carcinogenesis.

Molecular genetic analysis is of special importance for the diagnosis of collision tumors consisting of poorly differentiated neoplasms, such as peripheral T-cell lymphoma and anaplastic carcinoma, particularly when the results of immunohistochemistry are inconclusive. We believe that collision tumors consisting of large cell NHL and carcinoma would be detected more often if molecular genetic analysis were used more extensively \[[@B4]\]. Although we were unable to identify any common etiologic factor of the two malignancies in our patient, we believe that their synchronous presentation is purely coincidental. Nevertheless, in addition to its uniqueness, the situation of this patient offers several therapeutic challenges for clinicians. The advanced age of the patient, metastatic colorectal cancer, the influence of one malignancy on the natural history of another, and extra-pulmonary TB increased the complexity of treatment.

There are some hypotheses suggesting the etiology of collision tumors. One hypothesis is that the two primary tumors arise in continuity through a chance accidental 'meeting'. On the contrary, to date, there are no known common etiologic factors for the occurrence of both adenocarcinoma and malignant lymphoma in the colon. Another hypothesis is that the presence of the first tumor alters the microenvironment, precipitating the development of the second adjacent tumor \[[@B7]\].

In our case, the pre-operative examinations were unable to reveal lymphoma adjacent to adenocarcinoma. Further intensive investigations may help to detect the existence of collision tumors. Herein, we reported a rare case of collision tumors (adenocarcinoma and low-grade B-cell lymphoma) in the colon. A therapeutic dilemma exists in deciding the course of treatment in patients with collision tumors. Collision tumors of two types, similar to the current case, were previously observed in 8 patients, as listed in Table [1](#T1){ref-type="table"}. The age of the patients ranged from 59 to 81 years, with a mean age of 68.9 years. The male to female ratio was 3:1. Adenocarcinomas and lymphomas were located in the right colon, left colon, and rectum in 5, 1, and 3 patients, respectively. Previous reports have been limited because of the rarity of such collision tumors, and most reports did not describe the course of the disease after diagnosis. Sasaki et al. \[[@B6]\] reported that a patient received six courses of combined chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone regimen with rituximab) against malignant lymphoma, which yielded a complete response. In our case, the patient underwent six courses of chemotherapy with mFOLFOX6 followed by capecitabine to treat sigmoid colon adenocarcinoma with lung metastasis. Takashi et al. \[[@B7]\] reported a patient who died because of the peritoneal recurrence of malignant lymphoma.

###### 

Cases of collision tumors of primary malignant lymphoma and adenocarcinoma in the colon reported

  **Source**                       **Year**   **Age (years)/Sex**   **Tumor location**   **Tumor type**                  **Pathological stage**   **Treatment**      **Prognosis**
  -------------------------------- ---------- --------------------- -------------------- ------------------------------- ------------------------ ------------------ -----------------------------
  Cornes et al. \[[@B1]\]          1960       63/M                  Rectum               Lymphocytic lymphosarcoma       pT~3~N~0~M~0~            NA                 NA
  Aitani et al. \[[@B2]\]          1987       59/M                  Transverse colon     Diffuse large B-cell lymphoma   NA                       NA                 Alive
  Chazouillères et al. \[[@B3]\]   1990       56/F                  Rectum               Lymphoma                        NA                       NA                 NA
  Mannweiler et al. \[[@B4]\]      2003       73/M                  Rectum               T-cell lymphoma                 pT~2~N~0~M~0~            NA                 NA
  Minato et al. \[[@B5]\]          2004       80/M                  Ascending colon      Diffuse large B-cell lymphoma   NA                       NA                 5 months, died of pneumonia
  Sasaki et al. \[[@B6]\]          2010       62/M                  Cecum                Follicular lymphoma             pT~3~N~0~M~0~            CHOP + Rituximab   Alive
  Takashi et al. \[[@B7]\]         2011       76/F                  Ileocecal            Diffuse large B-cell lymphoma   pT~3~N~1~M~0~            NA                 5 months, died of lymphoma
  Chang et al. \[[@B8]\]           2011       NA                    Ileocecal            Diffuse large B-cell lymphoma   NA                       NA                 NA
  Our case                         2014       81/M                  Sigmoid colon        Low-grade B-cell lymphoma       pT~3~N~1a~M~1~           mFOLFOX6           Alive

NA, Not available; CHOP, Cyclophosphamide, doxorubicin, vincristine, and prednisone; mFOLFOX, Modified fluorouracil, leucovorin, and oxaliplatin.

Conclusions
===========

This clinical course clearly suggested the difficulty of selecting the optimal therapy for collision tumors of different malignant entities, and the importance of close follow-up for both lesions. More cases should be reported in the literature to define the principle management in such challenging scenarios. Moreover, pathologists should be aware of the existence of collision tumors in the small and large intestines. The appropriate selection of immunohistochemical tests may help to establish the diagnosis. Immunohistochemical results can be resolved by molecular analysis, particularly when lymphomas are components of collision tumors of the colon.
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